<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Psychiatric Hospitalizations Involving Methamphetamine Increased, Study Finds

Most psychiatric hospitalizations did not involve substances, however, and opioid-involved encounters decreased

minute read

by Kelsea Pieters | August 16, 2024
A view of the research bridge on the CU Anschutz Medical Campus

A new study, out now in Drug and Alcohol Dependence, that details trends among psychiatric hospitalizations between 2015-2019 finds that while most hospitalizations did not involve any substances, methamphetamine-related hospitalizations have increased while overall number of psychiatric hospitalizations remained stable.

Additionally, researchers detail that psychiatric hospitalizations caused by methamphetamine use were highest in the Mountain West region but were also shifting geographically.

“Rates of methamphetamine-involved psychiatric hospitalizations were by far the highest in the Mountain West," said Susan Calcaterra, MD, MPH, professor at the University of Colorado Anschutz Medical Campus and study lead author. "As expected, this mirrors rates of self-reported methamphetamine use and methamphetamine-related overdose deaths in the Mountain West," Calcaterra said. "Psychiatric hospitalizations involving methamphetamine use is really taking off in the Midwest and Northeast, in particular.”

Study underscores need for clinic-based harm-reduction tactics

While rates of methamphetamine-related psychiatric hospitalizations increased 68% over the study period, opioid-related hospitalizations decreased by 22%. Methamphetamine rate increases may be attributed to methamphetamine's ubiquitousness and affordability, as well as the lack of resources available to manage methamphetamine use. Why opioid-involved psychiatric hospitalizations declined is less clear but may be related to the lethality of fentanyl.

“An important takeaway from this study is the need for resources to address the mental and physical treatment of methamphetamine use,” Calcaterra said.

“While the vast majority of psychiatric hospitalizations in this timeframe did not involve substance use, the significant increase in methamphetamine use means we have to better consider harm reduction in clinical settings," she said.

"Evidence-based interventions such as contingency management, which involves offering incentives for abstinence, harm reduction education, provision of naloxone for overdose reversal and access to expanded mental health treatments are proven to help mitigate dangerous effects from methamphetamine use, especially when contaminated with fentanyl much like the campaigns aimed at public awareness around opioid use.”

Topics: Press Releases

Featured Experts
Staff Mention

Susan Calcaterra, MD, MPH